StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) income statement

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$5.94−0.08 (-1.33%)

Close on Nov 18, 2026Market cap $1.30BP/E –Yield –

Ocular Therapeutix, Inc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
87.1%
Operating margin
-603.0%
Net margin
-579.1%
Return on equity, FY2025
-54.9%

Financial strength

Current ratio
13.11
Debt to equity
0.14
Debt to assets
10.8%
Cash to current liabilities
1217.4%

Valuation

P/E ratio
–
Price to sales
25.06
Price to book
2.51
Dividend yield
–

See a number that looks wrong?